Table 1.
Baseline demographic, clinical and laboratory data of the study cohort.
| Characteristics | LA+ TE+ (n = 31) | LA+ TE− (n = 16) | Controls (n = 47) |
|---|---|---|---|
| Median age at study entry, y (IQR) | 45 (36–52) | 50 (35–68.5) | 48 (31–56) |
| Female, n (%) | 24 (77.4) | 12 (75) | 36 (78.7) |
| Smoking, n (%) | 6 (19.4) | 4 (25) | 5 (10.6) |
| Median laboratory values (IQR) | |||
| Platelet count × 109 /L | 226 (190–252) | 206 (124–250) | 262 (213–284) |
| MPV (xL fl) | 10.4 (9.6–10.9) | 10.6 (10.3–11.3) | 10.5 (9.9–11.6) |
| Neutrophil count (%) | 62 (58–68) | 62.5 (56–69) | 58.5 (54.5–64) |
| History of TE, n (%) | 31 (100) | 0 (0) | 0 (0) |
| Arterial TE | 7 (22.6) | 0 (0) | 0 (0) |
| Venous TE | 22 (71) | 0 (0) | 0 (0) |
| Arterial and venous TE | 2 (6.4) | 0 (0) | 0 (0) |
| Pregnancy complicationsa, n (%) | 11 (35.5) | 6 (37.5) | 0 (0) |
| aPLAs, n (%) | |||
| LA aloneb | 2 (6.5) | 8 (50) | |
| LA+ anti–ß2GPIc | 0 (0) | 0 (0) | |
| LA+ aCLc | 12 (38.7) | 3 (18.8) | |
| LA+ anti-ß2GPI + aCL (triple positivity)c | 17 (54.8) | 5 (31.2) | |
| Antithrombotic agent, n (%) | 24 (77.4) | 4 (25) | 0 (0) |
| VKA | 19 (61.3) | 1 (6.2)d | 0 (0) |
| LMWH | 2 (6.5) | 0 (0) | 0 (0) |
| DOACs | 2 (6.5) | 0 (0) | 0 (0) |
| LDA | 5 (16.1) | 3 (18.8)e | 0 (0) |
| Clopidogrel | 1 (3.2) | 0 (0) | 0 (0) |
| None | 7 (22.6) | 12 (75) | 0 (0) |
| Concomitant ARD, n (%) | 8 (25.8) | 3 (18.8) | 0 (0) |
| Hypertension, n (%) | 10 (32.3) | 6 (37.5) | 8 (17) |
| Hyperlipidaemia, n (%) | 4 (12.9) | 3 (18.8) | 1 (2.1) |
| Diabetes mellitus type 2, n (%) | 2 (6.5) | 1 (6.3) | 0 (0) |
| Hydroxychloroquine, n (%) | 3 (9.7) | 0 (0) | 0 (0) |
y years, n number, IQR interquartile range, LA lupus anticoagulant, TE thromboembolism, ß2GPI beta-2 glycoprotein, aCL anti-cardiolipin antibodies, VKA vitamin K antagonist, LMWH low-molecular-weight heparin, DOACs direct oral anticoagulants, LDA low-dose aspirin, ARD autoimmune rheumatic disease
aPatients with at least one pregnancy (LA+ TE+ n = 20; LA+ TE− n = 12; Healthy n = 22). Pregnancy complications were defined according to current criteria1
bLA alone defined as the absence of IgG/IgM anti-β2GPI and aCL
cCutoff: anti-β2GPI >8 GPL/MPL U/mL, aCL >40 GPL/MPL U/mL
dDue to atrial fibrillation
eDue to cardiovascular risk